203 related articles for article (PubMed ID: 22563374)
21. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
22. Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif.
Zhu Y; Rudensky AY; Corper AL; Teyton L; Wilson IA
J Mol Biol; 2003 Feb; 326(4):1157-74. PubMed ID: 12589760
[TBL] [Abstract][Full Text] [Related]
23. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
24. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner.
Gautam AM; Yang M; Milburn PJ; Baker R; Bhatnagar A; McCluskey J; Boston T
J Immunol; 1997 Sep; 159(6):2782-8. PubMed ID: 9300699
[TBL] [Abstract][Full Text] [Related]
25. Exogenous CLIP localizes into endocytic compartment of cells upon internalization: implications for antigen presentation by MHC class II molecules.
Mukherjee R; Chaturvedi P; Lee-Chan E; Singh B
Mol Immunol; 2008 Apr; 45(8):2166-76. PubMed ID: 18279957
[TBL] [Abstract][Full Text] [Related]
26. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
[TBL] [Abstract][Full Text] [Related]
27. Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex.
Schlundt A; Günther S; Sticht J; Wieczorek M; Roske Y; Heinemann U; Freund C
J Mol Biol; 2012 Oct; 423(3):294-302. PubMed ID: 22820093
[TBL] [Abstract][Full Text] [Related]
28. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP
Anczurowski M; Yamashita Y; Nakatsugawa M; Ochi T; Kagoya Y; Guo T; Wang CH; Rahman MA; Saso K; Butler MO; Hirano N
Sci Rep; 2018 Mar; 8(1):4804. PubMed ID: 29555965
[TBL] [Abstract][Full Text] [Related]
30. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
31. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules.
Wu S; Gorski J
Mol Immunol; 1996; 33(4-5):371-7. PubMed ID: 8676888
[TBL] [Abstract][Full Text] [Related]
32. Posttranslational regulation of I-Ed by affinity for CLIP.
Rinderknecht CH; Belmares MP; Catanzarite TL; Bankovich AJ; Holmes TH; Garcia KC; Nanda NK; Busch R; Kovats S; Mellins ED
J Immunol; 2007 Nov; 179(9):5907-15. PubMed ID: 17947664
[TBL] [Abstract][Full Text] [Related]
33. DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms.
Rinderknecht CH; Roh S; Pashine A; Belmares MP; Patil NS; Lu N; Truong P; Hou T; Macaubas C; Yoon T; Wang N; Busch R; Mellins ED
Immunology; 2010 Sep; 131(1):18-32. PubMed ID: 20408893
[TBL] [Abstract][Full Text] [Related]
34. CLIP-region mediated interaction of Invariant chain with MHC class I molecules.
Powis SJ
FEBS Lett; 2006 May; 580(13):3112-6. PubMed ID: 16678175
[TBL] [Abstract][Full Text] [Related]
35. Clip binds to HLA class II using methionine-based, allele-dependent motifs as well as allele-independent supermotifs.
Geluk A; Van Meijgaarden KE; Drijfhout JW; Ottenhoff TH
Mol Immunol; 1995 Sep; 32(13):975-81. PubMed ID: 7477003
[TBL] [Abstract][Full Text] [Related]
36. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
37. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM.
Vogt AB; Kropshofer H; Moldenhauer G; Hämmerling GJ
Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9724-9. PubMed ID: 8790398
[TBL] [Abstract][Full Text] [Related]
38. Truncation of the class II beta-chain cytoplasmic domain influences the level of class II/invariant chain-derived peptide complexes.
Smiley ST; Rudensky AY; Glimcher LH; Grusby MJ
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):241-4. PubMed ID: 8552613
[TBL] [Abstract][Full Text] [Related]
39. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
40. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
